An interventional study of Interval training in Atrial Fibrillation, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-01-08.
Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Prevention
The purpose of this study is to determine the effect of aerobic interval training in patients with paroxysmal or persistent atrial fibrillation, especially to see if the burden of atrial fibrillation and symptoms are reduced.
Long term endurance sport practice is associated with a higher incidence of atrial fibrillation. Moderate/light physical activity seems to be associated with a lower incidence. The underlying mechanisms are uncertain. In order to examine the effect of training in this population, the investigators will perform a randomised controlled study with aerobic interval training in patients with paroxysmal/persistent atrial fibrillation.
3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.
This study's enrollment of 51 is below the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Norwegian University of Science and Technology is the lead sponsor of 487 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Interval training
Behavioral: Interval training
Live as usual
Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
Change in burden of atrial fibrillation
Burden of atrial fibrillation(number of episodes, duration(percent of the day)) continually measured, and reported by the patient. Analysed for the patients in total, with sub analysis in the groups of paroxysmal and persistent AF and in those with a low burden of atrial fibrillation vs. those with a larger burden.
Time frame: Baseline and 4 weeks after ended intervention period
Size of left atrium and ventricle
Atrial and ventricular size will be evaluated by echocardiography and MRI.
Time frame: Baseline and after ended intervention period(12 weeks)
Blood samples
Interleukin-6, pro-BNP, d-dimer and von Willenbrands factor are measured.
Time frame: Baseline and after ended intervention period(12 weeks)
Endothelial function
FMD
Time frame: Baseline and after ended intervention period(12 weeks)
Atrial extrasystoles
Atrial extrasystoles on 48h Holter monitoring. Will alse be measured in the first week of training.
Time frame: Baseline and after ended intervention period(12 weeks)
Ablation procedure
Duration of ablation, number of ablation points, success.
Time frame: Measured during the ablation procedure (day 1)
Maximal oxygen uptake
Time frame: Baseline and after ended intervention period(12 weeks)
Atrial and ventricular function
Atrial and ventricular function measured by MR and echocardiography
Time frame: Baseline and after ended intervention period(12 weeks)
Fibrosis
Fibrosis in left atrium and left ventricle measured by MRI.
Time frame: Baseline and after ended intervention period(12 weeks)
Quality of life
Measured with SF-36, Symptom and Severity Checklist and EHRA score of AF- related symptoms
Time frame: Baseline and after ended intervention period(12 weeks)
Burden of atrial fibrillation in the intervention period
The intervention period is divided into 3 periods of 4 weeks each. The mean burden of atrial fibrillation(percent of time with atrial fibrillation) and number of episodes in each of those periods will be assessed to see if exercise changes the amount of fibrillation.
Time frame: Week 1-4, 5-8 and 9-12
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology